Biotech Volatile Stocks: Coronado Biosciences Inc (NASDAQ:CNDO), Idera Pharmaceuticals Inc (NASDAQ:IDRA), OHR Pharmaceutical Inc (NASDAQ:OHRP), XenoPort, Inc. (NASDAQ:XNPT)

Posted by on May 16, 2014

On May 12, 2014, Coronado Biosciences Inc (NASDAQ:CNDO), announced its financial results for the first quarter ended March 31, 2014. Net loss was $7.4 million, or $0.21 per share, for the first quarter of 2014 compared to a net loss of $8.9 million, or $0.35 per share, for the first quarter of 2013. Research and development expenses were $4.5 million for the first quarter of 2014, compared to $6.0 million for the first quarter of 2013. General and administrative expenses were $2.1 million for the first quarter of 2014, compared to $2.5 million for the first quarter of 2013. Coronado Biosciences Inc (NASDAQ:CNDO), weekly performance is 11.54%. On last trading day company shares ended up $1.74. Analysts mean target price for the company is $1.90. Coronado Biosciences Inc (NASDAQ:CNDO), distance from 50-day simple moving average (SMA50) is -11.58%.

On May 13, 2014, Idera Pharmaceuticals Inc (NASDAQ:IDRA), reported Q1 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Idera Pharmaceuticals Inc (NASDAQ:IDRA), advanced 2.65% in last trading session and ended the day on $2.71. IDRA, return on assets is -84.10%. Idera Pharmaceuticals Inc (NASDAQ:IDRA), quarterly performance is -38.41%.

OHR Pharmaceutical Inc (NASDAQ:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced that it has entered into a definitive agreement with privately held SKS Ocular LLC and its affiliate SKS Ocular 1 LLC (“SKS Ocular”) to acquire SKS Ocular’s ophthalmology assets. OHR Pharmaceutical Inc (NASDAQ:OHRP), shares moved up 9.74% in last trading session and was closed at $8.90, while trading in range of $7.89 – 9.06. OHR Pharmaceutical Inc (NASDAQ:OHRP), year to date (YTD) performance is 12.94%.

Reckitt Benckiser Pharmaceuticals Inc. and XenoPort, Inc. (NASDAQ:XNPT), announced that they have entered into a license agreement pursuant to which Reckitt Benckiser Pharmaceuticals will be granted exclusive worldwide rights for the development and commercialization of XenoPort’s clinical-stage oral product candidate arbaclofen placarbil for all indications. XenoPort, Inc. (NASDAQ:XNPT), ended the last trading day at $3.66. Company weekly volatility is calculated as 9.39% and price to cash ratio as 3.85. XenoPort, Inc. (NASDAQ:XNPT), showed a positive weekly performance of 2.23%.

Leave a Reply